Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00065182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

399

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Non-Small Cell
Non-Small-Cell Lung Cancer

Interventions

DRUG: Topotecan/Docetaxel combination
DRUG: Docetaxel

Sponsor

GlaxoSmithKline